Article
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.
Cancer discovery - 1 Nov 2024
Dilly Julien, Hoffman Megan T, Abbassi Laleh, Li Ziyue, Paradiso Francesca, Parent Brendan D, Hennessey Connor J, Jordan Alexander C, Morgado Micaela, Dasgupta Shatavisha, Uribe Giselle A, Yang Annan, Kapner Kevin S, Hambitzer Felix P, Qiang Li, Feng Hanrong, Geisberg Jacob, Wang Junning, Evans Kyle E, Lyu Hengyu, Schalck Aislyn, Feng Ningping, Lopez Anastasia M, Bristow Christopher A, Kim Michael P, Rajapakshe Kimal I, Bahrambeigi Vahid, Roth Jennifer A, Garg Kavita, Guerrero Paola A, Stanger Ben Z, Cristea Simona, Lowe Scott W, Baslan Timour, Van Allen Eliezer M, Mancias Joseph D, Chan Emily, Anderson Abraham, Katlinskaya Yuliya V, Shalek Alex K, Hong David S, Pant Shubham, Hallin Jill, Anderes Kenna, Olson Peter, Heffernan Timothy P, Chugh Seema, Christensen James G, Maitra Anirban, Wolpin Brian M, Raghavan Srivatsan, Nowak Jonathan A, Winter Peter S, Dougan Stephanie K, Aguirre Andrew J
Abstract excerpt
KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, mutations in PIK3CA and KRAS, and amplifications of KRASG12C, MYC, MET, EGFR, and CDK6 emerged at acquired resistance. In PDAC cell lines and organoid models treated with the KRASG12D inhibitor MRTX1133,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.